For first time in 40 years, cure for acute leukemia within reach

August 24, 2018 by Tali Aronsky, Hebrew University of Jerusalem
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.

As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)'s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for with .

Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.

To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during "targeted therapy" treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.

However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.

Additionally promising, is the new drug's ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.

"We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice's' signs disappeared overnight," shared professor Ben-Neriah.

BioTheryX recently bought the rights to this promising drug from HU's technology transfer company Yissum. Together with Ben-Neriah's research team, they are now applying for FDA approval for phase I clinical studies.

Explore further: Protein networks help identify new chemo drug candidates

More information: Waleed Minzel et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models, Cell (2018). DOI: 10.1016/j.cell.2018.07.045

Related Stories

Protein networks help identify new chemo drug candidates

November 26, 2015
An experimental chemotherapy kills leukemia cells that are abundant in proteins critical to cancer growth, according to new research from Weill Cornell Medicine.

Single surface protein boosts multiple oncogenic pathways in acute myeloid leukemia

May 17, 2018
Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. ...

Anti-malaria drug increases sensitivity of high-risk leukemic cells to targeted therapy

December 4, 2017
St. Jude Children's Research Hospital scientists have evidence that an anti-malaria drug sensitizes a high-risk subtype of acute lymphoblastic leukemia (ALL) to treatment with a promising class of targeted drugs, raising ...

Bolstering fat cells offers potential new leukemia treatment

October 16, 2017
Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, according to a new study from McMaster University.

Promising drug a 'new paradigm' for treating leukemia

March 25, 2015
Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved ...

Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors

September 6, 2016
Although chemotherapy can sometimes cure acute myeloid leukemia and other hematologic cancers, many patients experience relapses when their tumors become resistant to available chemotherapies. This resistance may be caused ...

Recommended for you

Pancreatic cancer's addiction could be its end

November 13, 2018
Cancer cells are often described as cells "gone bad" or "renegade." New research reveals that in some of the deadliest cases of pancreatic cancer, these rebellious cells have an unexpected addiction. Now, scientists are investigating ...

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

Study finds promising therapeutic target for aggressive type of breast cancer

November 13, 2018
A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a potential therapeutic target for triple negative ...

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

NoStrings
5 / 5 (1) Aug 26, 2018
Have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.

cure for acute leukemia within reach != drug with a cure rate of 50% for lab mice

I would bet a lot on unlikelihood of any drug approval coming out of clinical trial, if there ever is one

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.